Abstract:Introduction The specific mechanism that can explain the linking of Citomegalovirus (CMV) infection with diminished graft function is not totally clear due to there are numerous issues involved. Some cytokines with antiviral proprieties such as interferon gamma (IFN-&ggr;) have been studied. In fact, the SNP +874 A/T of IFN-&ggr; gene, which is linked to their levels, has been associated with increased risk of CMV infection in both lung and kidney transplant recipients. Our purpose was to replicate the association of this SNPin an independent population of kidney transplant patients. Materials and Methods A retrospective analysis was performed in 600 consecutive transplanted kidney recipients. The SNP+874 A/T (rs2430561) was genotyped by TaqMan chemistry under conditions recommended by manufacturer and analyzed in a 7900HT Fast Real-Time PCR System (Applied Biosystem, Foster City, CA, USA). CMV viral load was determined by quantitative nucleic acid amplification testing (QNAT). Results and Discussion Patients with CMV infection were 205 (34.2%) and the median time after transplant to the onset of CMV infection was 2.7 months (range 1.2-5.3 months).We found no association of IFN-&ggr;+874 A/T polymorphism in either univariate or multivariate analyses and regardless of prophylactic treatment with valganciclovir (Tables 1 and 2). Due to antiviral properties of this cytokine and the implication of the aforementioned polymorphism in their level, it would seem the most appropriate approach to assess the risk of CMV infection; however, this association could not be stablished in our well powered cohort. The previously reported association of IFN-&ggr; +874 A/T polymorphism with CMV infection in kidney transplant and lung transplant recipients showed 52 and 42 CMV positives patients respectively. In the adjusted model we found interactions between prophylaxis with status CMV D+ / R- (P-interaction = 0.010), with thymoglobulin induction therapy (P-interaction = 0.034) and with thymoglobulin anti-rejection therapy (P-interaction = 0.002). Data showed that CMV seropositive recipients and no thymoglobulin therapy, the prophylaxis with valganciclovir is not an advantage (Table 2); however if thymoglobulin is used for induction and/or rejection, valganciclovir profilaxis is a protective key for CMV infection (Table 2). Related to well-known associated factors, increased infection risk was observed for recipient age, delayed graft function and (initial immunosuppressive treatment with mammalian target of rapamycin inhibitors (mTORi), (Table 2). Table. No title available. Table. No title available. Conclusion Our data suggest that IFN-&ggr; +874 A/T polymorphism is not a predictive marker of CMV infection in a Spanish cohort of kidney transplant patients, the thymoglobulin therapy is not a risk factor for CMV infection when it is associated with prophylaxis with valganciclovir and the protective effect of imTORis not improved with prophylactic treatment.

Cellular immunity against cytomegalovirus and risk of infection after kidney transplantation

The Impact of Pretransplant Cytomegalovirus Infection on Acute Renal Allograft Rejection

A prospective study of the predictive value of polymerase chain reaction assay for cytomegalovirus in asymptomatic kidney transplant recipients

CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality

Early Immune Surveillance to Predict Cytomegalovirus Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation.

Methodology for Monitoring Cytomegalovirus Infection after Renal Transplantation

Tailoring cytomegalovirus prophylaxis based on T cell immunity panel assessment in kidney transplant patients at high risk of cytomegalovirus

Utility of the Interferon-Gamma Enzyme-Linked Immunosorbent Spot Assay to Predict Risk of Cytomegalovirus Infection in Kidney Transplant Recipients

Impact of an ultrasensitive Cytomegalovirus quantitative nucleic acid test on Cytomegalovirus detection and therapy in renal transplant recipients

Five‐year single‐center analysis of cytomegalovirus viremia in kidney transplant recipients and possible implication for novel prophylactic therapy approaches

Evolving trends in immunosuppression use and cytomegalovirus infection risk over the past decade in kidney transplantation

The Association Between Cytomegalovirus Infection and Kidney Damage in the Liver Transplant Setting

Anti-Donor T-Cell Responses Are Not Necessarily Attenuated During Cytomegalovirus Infection in Kidney Transplant Recipients

Risk factors for cytomegalovirus infection and disease after kidney transplantation: A meta-analysis

Gastrointestinal Cytomegalovirus Infection in a Transplantation Recipient With a Negative Serum Viral Load: Case Report

High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function

[Cytomegalovirus Infection Monitoring in Patients with Long-Term Survival after Allogeneic Hematopoietic Stem Cell Transplantation].

Treatment Of Cytomegalovirus Infection After Renal Transplantation: Experience From A Single Center In China

Pre-Transplant Frequencies of FoxP3+CD25+ in CD3+CD8+ T Cells as Potential Predictors for CMV in CMV-Intermediate Risk Kidney Transplant Recipients

Cytomegalovirus Post-Prophylaxis Surveillance in High-Risk Kidney and Liver Recipients Prevents CMV End-Organ Disease and Ganciclovir-Resistance

Effect of Interferon-Gamma Gene Polymorphism +874 A/T on Cytomegalovirus Infection in Kidney Transplant Recipients With and Without Prophylactic Treatment with Valganciclovir